Butyrylcholinesterase: An enzyme antidote for cocaine intoxication

Addiction Biology

Volumn 3, Issue 2, 1998, Pages 171-188

  Mattes, Carol E ^a,b,c   Belendiuk, George W ^a   Lynch, Thomas J ^a,e   Brady, Roscoe O ^d   Dretchen, Kenneth L ^b  

^a Pharmavene Inc   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d US Food and Drug Administration ^*  (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; BENZOYLECGONINE; CHOLINESTERASE; COCAINE; ECGONINE METHYL ESTER; NORCOCAINE;

ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CONVULSION; DRUG ABUSE; DRUG INTOXICATION; DRUG METABOLISM; HUMAN; HYPERACTIVITY; HYPERTENSION; METABOLITE; PRIORITY JOURNAL;

EID: 0031897380     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556219872236     Document Type: Article

References (105)

1. Creigler LL, Mark H. Cardiovascular dangers of cocaine abuse. Am J Cardiol 1986;57:1185-6.
2. Merigan KS, Park LJ, Leeper KV, Browning RG, Giometi R. Adrenergic crisis from crack cocaine ingestion: report of five cases. J Emerg Med 1994; 12:485-90.
3. Nolte KB, Brass LM, Fletterick CF. Intracranial hemorrhage associated with cocaine abuse. Neurology 1996;46:1291-6.
4. Sehgal S, Ewing C, Waring R, Findlay R, Bean X, Taeusch HW. Morbidity of low-birth weight infants with intrauterine cocaine exposure. J Nat Med Assoc 1993;85:20-4.
5. Mendelson JH, Mello NK. Management of cocaine abuse and dependence. N Engl J Med 1996;334:965-72.
6. Wiggins RC. Pharmacokinetics of cocaine in pregnancy and effects on fetal maturation. Clin Pharmacokinet 1992;22:85-93.
7. Plessinger MA, Woods JR. Maternal, placental and fetal pathophysiology of cocaine exposure during pregnancy. Clin Obstet Gynecol 1993;36: 267-78.
8. Mott SH, Packer RJ, Soldin S. Neurologic manifestations of cocaine exposure in childhood. Pediatrics 1994;93:557-60.
9. Marzuk PM, Tardiff K, Leon AC, et al. Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med 1995;332:1753-7.
10. Isner JM, Estes NA, Thompson PD, et al. Acute cardiac events temporally related to cocaine usage. N Engl J Med 1986;315:1438-43.
11. Nelson L, Hoffman RS. How to manage acute MI when the cause is cocaine. J Crit Illness 1995;10: 39-43.
12. Hollander JE, Hoffman RS, Burstein JL, Shih RD, Thode HC. Cocaine-associated myocardial infarction. Arch Intern Med 1995;155:1081-6.
13. Wilkerson RD. Cardiovascular effects of cocaine in conscious dogs: importance of fully functional autonomic and central nervous systems. J Pharmacol Exp Ther 1988;246:466-71.
14. Branch CA, Knuepfer M. Causes of differential cardiovascular sensitivity to cocaine II: sympathetic, metabolic and cardiac effects. J Pharmacol Exp Ther 1994;271:1103-13.
15. Branch CA, Knuepfer MM. Causes of differential cardiovascular sensitivity to cocaine I: studies in conscious rats. J Pharmacol Exp Ther 1994;269: 674-83.
16. Brogan WC, Lange RA, Glamann B, Hillis LD. Recurrent coronary vasoconstriction caused by intranasal cocaine: possible role for metabolites. Ann Intern Med 1992;116:556-61.
17. Creigler LL. Cocaine: the newest risk factor for cardiovascular disease. Clin Cardiol 1991;14: 449-56.
18. Stathis M, Scheffel U, Lever SZ, Boja JW, Carroll FI, Kuhlar MJ. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology 1995;119:376-84.
19. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-7.
20. Rothman RB, Silverthorn ML, Baumann MH, et al. Studies of the biogenic amine transporters. J Pharmacol Exp Ther 1995;274:385-95.
21. 3H-win 35,428. Synapse 1989;4: 390-2.
22. Scheffel U, Pogun S, Stathis M, Boja JW, Kuhlar MJ. In vivo labeling of cocaine binding sites on doparmine transporters with 3H-WIN 35,428. J Pharrnacol Exp Ther 1991;257:954-8.
23. Ritz MC, Cone EJ, Kuhlar M. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990;46:635-45.
24. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299-302.
25. Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1996; 333:1267-72.
26. Sand IC, Brody SL, Wrenn KD, Slovis CM. Experience with esmolol for the treatment of cocaine-associated cardiovascular complications, Am J Emerg Med 1991;9:161-3.
27. Vargas R, Gillis RA, Ramwell PW. Propranolol promotes cocaine-induced spasm of porcine coronary artery. J Pharmacol Exp Ther 1991;257: 644-8.
28. Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, Cook CE. Cocaine disposition in humans after intravenous injection, nasal insufflation or smoking. Drug Metab Disposition 1989;17:153-9.
29. VanDyke C, Barash PG, Jatlow P, Byck R. Cocaine: plasma concentrations after intranasal application in man. Science 1976;191:859-61.
30. Ambre J. The urinary excretion of cocaine and metabolites in humans: a kinetic analysis of published data. J Analyt Toxicol 1985;9:241-5.
31. Mittleman RE, Cofino JC, Hearn WL. Tissue distribution of cocaine in a pregnant woman. J Forensic Sci 1989;34:481-6.
32. Speihler VR, Reed D. Brain concentrations of cocaine and benzoylecgonine in fatal cases. J Forensic Sci 1985;30:1003-11.
33. Ambre J, Ruo TI, Nelson J, Belkap S. Urinary excretion of cocaine, benzoylecgonine and ecgonine methylester in humans. J Analyt Toxicol 1988; 12:301-6.
34. Isenschmid DS, Levine BS, Caplan YH. A comprehensive study of the stability of cocaine and its metabolites. J Analyt Toxicol 1989;13:250-6.
35. Isenschmid DS, Fischman MW, Foltin RW, Caplan YH. Concentration of cocaine and metabolites in plasma of humans following administration and smoking of cocaine. J Analyt Toxicol 1992;16:311-14.
36. Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin Pharmacol Ther 1978;23: 547-52.
37. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver serum esterases. Clin Pharmacol Ther 1979;25:464-8.
38. Ambre J, Fischman M, Puo T. Urinary excretion of ecgonine methyl ester, a major metabolite of cocaine in humans. J Analyt Toxicol 1984;8:23-5.
39. Konkol RJ, Erickson BA, Doerr JK, Hoffman RG, Madden JA. Seizures induced by the cocaine metabolite benzoylecgonine in rats. Epilepsia 1992;33:420-7.
40. Spear LP, Frambes NA, Kirstein CL. Fetal and maternal brain and plasma levels of cocaine and benzoylecgonine following chronic subcutaneous administration of cocaine during gestation in rats. Psychopharmacology 1989;97:427-31.
41. Cone EJ, Yousefnejad D, Darwin WD, Maguire T. Testing human hair for drugs of abuse. II. Identification of unique cocaine metabolites in hair of drug abusers and evaluation of decontamination procedures. J Analyt Toxicol 1991;15:250-5.
42. Crumb WJ, Clarkson CW. Characterization of the sodium channel blocking properties of the major metabolites of cocaine in single cardiac myocytes. J Pharmacol Exp Ther 1992;261:910-17.
43. Schenker SS, Yang Y, Johnson RF, et al. The transfer of cocaine and its metabolites across the term human placenta. Clin Pharmacol Ther 1993; 53:329-39.
44. Stewart DJ, Inaba T, Tang BK, Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci 1977;20:1557-64.
45. Hawks RL, Kopin IJ, Colburn RW, Thoa NB. Norcocaine: a pharmacologically active metabolite of cocaine found in brain. Life Sci 1974;15: 2189-95.
46. Om A, Ellah S, Ornato JP, et al. Medical complications of cocaine: possible relationship to low plasma cholinesterase enzyme. Am Heart J 1993; 125:1114-17.
47. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 1992;21: 247-53.
48. Hoffman RS, Henry GC, Wax PM, Weisman RS, Howland MA, Goldfrank LR. Decreased plasma cholinesterase activity enhances cocaine toxicity in mice. J Pharmacol Exp Ther 1992;263:698-702.
49. Kambam J, Mets B, Hickman RM, et al. The effects of inhibition of plasma cholinesterase and hepatic microsomal enzyme activity on cocaine, benzoylecgonine, ecgonine methyl ester and norcocaine blood levels in pigs. J Lab Clin Med 1992; 120:323-8.
50. Jatlow JP, Barash PG, VanDyke C, Radding J, Byck R. Cocaine and succinylcholine sensitivity: a new caution. Anesth Analg 1979;59:235-8.
51. Matsubara K, Kagawa M, Fuki Y. In vivo and in vitro studies on cocaine metabolism: ecgonine methyl ester as a major metabolite of cocaine. Forensic Sci Int 1984;26:168-80.
52. Herschman Z, Aaron C. Prolongation of cocaine effect. Anesthesiology 1991;74:631-2.
53. Devenyi P. Cocaine complications and pseudo-cholinesterase. Ann Intern Med 1989;110:167-8.
54. Vellom DC, Radic Z, Li Y, Pickering NA, Camp S, Taylor P. Amino acid residues controlling acetylcholinesterase and buryrylcholinesterase specificity. Biochemistry 1993;32:12-17.
55. Taylor P. The cholinesterases. J Biol Chem 1989; 266:4025-8.
56. Lockridge O. Structure of human serum cholinesterase. BioEssays 1988;9:125-8.
57. Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989;260:625-34.
58. Lockridge O, Bartels CF, Vaughan TA, Wong CW, Norton SE, Johnson LL. Complete amino acid sequence of human serum cholinesterase. J Biol Chem 1987;262:549-57.
59. Arpagaus M, Katt M, Vatsis KP, Bartels CF, LaDu BN, Lockridge O. Structure of the gene for human butyrylcholinesterase: evidence for a single copy. Biochemistry 1990;29:124-31.
60. Prody CA, Zevin-Sonkin D, Gnatt A, Goldberg O, Soreq H. Isolation and characterization of full-length cDNA clones for cholinesterase from fetal human tissue. Proc Natl Acad Sci 1987;84: 3555-9.
61. Ordentlich A, Barak D, Kronman C, et al. Dissection of the human acetylcholinesterase active center determinants of substrate specificity. J Biol Chem 1993;268:17083-95.
62. Ordentlich A, Barak D, Kronman C, et al. Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylinesterase. J Biol Chem 1995;270:2082-91.
63. Gnatt A, Loewenstein Y, Yaron A, Schwarz M, Soreq H. Site-directed mutagenesis of active site residues reveals plasticity of human butyrylcholinesterase in substrate and inhibitor interactions. J Neurochem 1994;62:749-55.
64. Neville LF, Gnatt A, Padan R, Seidman S, Soreq H. Anionic site interactions in human butyrylcholinesterase by two single point mutations. J Biol Chem 1990;265:20735-8.
65. Warshel A, Naray-Szabo G, Sussman F, Hwang J-K. How do serine proteases really work? Biochemistry 1989;28:3629-37.
66. Lockridge O, LaDu BN. Comparison of atypical and usual human serum cholinesterase. J Biol Chem 1978;253:361-6.
67. Cohn EJ, Strong LE, Hughes WL, Mulford JN, Ashworthe M, Taylor HL. Preparations and properties of serum and plasma proteins IV. A system for the separation into fractions, the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-75.
68. Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, Dretchen KL. Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 1996;145:363-71.
69. Gatley SJ. Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol 1991;41:1249-54.
70. Mattes C, Bradley B, Slaughter E, Browne S. Cocaine and butyrylcholinesterase (BChE): determination of enzyme parameters. Life Sci 1996;58: PL257-62.
71. Landry DW, Zhao K, Yang X, Gliickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine. Science 1993;259:1899-901.
72. Browne SP, Slaughter EA, Couch RA, McLean AM, Rudnic EM. The influence of BChE concentration on the in vitro hydrolysis of cocaine in human plasma. Pharm Res 1995;12:S274.
73. Ostergaard D, Viby-Morgensen J, Hanel HK, Skovgaard LT. Half-life of plasma cholinesterase. Acta Anaesthesiol Scand 1988;32:266-9.
74. Stovner J, Stadskleiv K. Suxamethonium apnea terminated with commercial serum cholinesterase. Acta Anaesthesiol Scand 1976;20:211-15.
75. Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. Biochem Pharmacol 1993;45:2465-72.
76. Broomfield CA, Maxwell DM, Solana RP, Castro CA, Fingr AV, Lenz DE. Protection by butyrylcholinesterase against organophosphate poisoning in nonhuman primates. J Pharmacol Exp Ther 1991;259:633-8.
77. Mattes CE, Lynch TJ, Singh A, et al. Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 1997;145:372-80.
78. Temesy-Armos PN, Fraker TD, Brewster PS, Wilkerson RD. The effects of cocaine on cardiac electrophysiology in conscious, unsedated dogs. J Cardiovasc Pharmacol 1992;19:883-91.
79. Kabas JS, Blanchard SM, Matsuyama Y, et al. Cocaine-mediated impairment of cardiac conduction in the dog: a potential mechanism for sudden death after cocaine. J Pharmacol Exp Ther 1990; 252:185-91.
80. Benchimol A, Bartell H, Dessar KB. Accelerated ventricular rhythm and cocaine abuse. Ann Intern Med 1978;88:519-20.
81. Crumb WJ, Kadowitz PJ, Xu Y-Q, Clarkson CW. Electrocardiographic evidence for cocaine cardiotoxicity in cat. Can J Physiol Pharmacol 1990;68: 622-5.
82. Hale SL, Lehmann MH, Kloner RA. Electrocardiographic abnormalities after acute administration cocaine in the rat. Am J Cardiol 1989;63: 1529-30.
83. Jonsson S, O'Meara M, Young JB. Acute cocaine poisoning: importance of treating seizures and acidosis. Am J Med 1983;75:1061-4.
84. Nanji AA, Filipenko JD. Asystole and ventriculr fibrillation associated with cocaine intoxication. Chest 1984;85:132-3.
85. Schwartz AB, Janzen D, Jones RT, Boyle W. Electrocardiographic and hemodynamic effects of intravenous cocaine in awake and anesthetized dogs. J Electrocardiol 1989;22:159-66.
86. Raczkowski VFC, Hernandez YN, Erzouki HK, et al. Cocaine acts in the central nervous system to inhibit sympathetic neural activity. J Pharmacol Exp Ther 1991;257:511-19.
87. Ostergaard D, Jensen FS, Viby-Mogensen D. Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology 1995;82: 1295-8.
88. Scholler KL, Goedde HW, Benkmann HG. The use of serum cholinesterase in succinylcholine apnea. Can Anesthesiol Soc J 1977;24:396-400.
89. Viby-Mogensen J. Succinylcholine neuromuscular blockade in subjects homozygous for atypical plasma cholinesterase. Anesthesiology 1981;55: 429-34.
90. Naguib M, Daoud W, El-Gammal M, et al. Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase. Anesthesiology 1995;83:694-701.
91. Benzer A, Luz G, Oswald E, Schmoigl C, Menardi G. Succinylcholine-induced prolonged apnea in a 3-week old newborn: treatment with human plasma cholinesterase. Anesth Analg 1992;74: 137-8.
92. Wolfe AD, Blick DW, Murphy MR, et al. Use of cholinesterase as pretreatment drugs for the protection of Rhesus monkeys against soman toxicity. Toxicol Appl Pharmacol 1992;117:189-93.
93. Raveh L, Ashani Y, Levy D, DeLaHoz D, Wolfe AD, Doctor BP. Acetylcholinesterase prophylaxis against organophosphate poisoning. Biochem Pharmacol 1989;38:529-34.
94. Ostergaard D, Jensen FS, Skovgaard LT, Viby-Mogensen J. Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patients. Acta Anesthesiol Scand 1992;36:702-6.
95. Kalow W. The relation of plasma cholinesterases to response to clinical doses of succinylcholine. Can Anesthesiol Soc J 1956;3:22-30.
96. Goudsouzian NG, Hollander SS, Viby-Mogensen J. Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency. Anesth Analg 1993;77:183-5.
97. Ali HH, Savarese Jj, Embree PB, et al. Clinical pharmacology of mivacurium chloride infusion: comparison with vecuronium and atracurium. Br J Anesthesiol 1988;61:541-6.
98. Whittaker M. Plasma variants and the anesthetist. Anaesthesia 1980;35:174-97.
99. Whittaker VP. The cholinesterases]discussion of some unanswered questions. Prog Brain Res 1993;98:155-9.
100. Seto Y, Shinohara T. Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch Toxicol 1988;62:37-40.
101. Katz A, Hoffman RS, Silverman RA. Phenytoin toxicity from smoking crack cocaine adultered with phenytoin. Ann Emerg Med 1993;22: 1485-7.
102. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphate insecticides. N Engl J Med 1987;316:761-3.
103. Ashani Y, Shapira S, Levy D, Wolfe AD, Doctor BP, Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem J 1991;41:37-41.
104. Winecoff AP, Hariman RJ, Grawe JJ, Wang Y, Bauman JL. Reversal of the electrocardiographic effects of cocaine by lidocaine. Pharmacotherapy 1994;14:698-703.
105. Fraker TD, Temesy-Armos PN, Brewster PS, Wilkerson RD. Interaction of propranolol, verapamil, and nifedipine on the myocardial depressant effect of cocaine. J Cardiovasc Pharmacol 1995; 25:579-86.